Lundbeck today announced that its investigational drug bexicaserin, for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), has been granted Breakthrough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback